COPD Trials Would Need New Endpoints Under Draft FDA Guidance; FEV Is Out
Executive Summary
Primary and secondary endpoints for Phase III studies of drugs used to treat chronic obstructive pulmonary disease should be chosen based on the drug's purported mechanism of action and the clinical indication sought, FDA says in a draft guidance